LANOXIN PEDIATRIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lanoxin Pediatric, and when can generic versions of Lanoxin Pediatric launch?
Lanoxin Pediatric is a drug marketed by Covis and is included in one NDA.
The generic ingredient in LANOXIN PEDIATRIC is digoxin. There are ten drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the digoxin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lanoxin Pediatric
A generic version of LANOXIN PEDIATRIC was approved as digoxin by RISING on December 23rd, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LANOXIN PEDIATRIC?
- What are the global sales for LANOXIN PEDIATRIC?
- What is Average Wholesale Price for LANOXIN PEDIATRIC?
Summary for LANOXIN PEDIATRIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 18 |
| DailyMed Link: | LANOXIN PEDIATRIC at DailyMed |
Recent Clinical Trials for LANOXIN PEDIATRIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Turning Point Therapeutics, Inc. | Phase 1 |
| Yale University | Phase 2 |
| Jean Grem, MD | Phase 2 |
Pharmacology for LANOXIN PEDIATRIC
| Drug Class | Cardiac Glycoside |
US Patents and Regulatory Information for LANOXIN PEDIATRIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covis | LANOXIN PEDIATRIC | digoxin | INJECTABLE;INJECTION | 009330-004 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
